779 A phase 1/2, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors by Aung Naing, Emiliano Calvo, Chen Zhu, Martin Gutierrez, Elena Garralda, Giovanni Abbadessa, Helene Guillemin-Paveau, Meijing Wu, Raymond Perez, Marloes van Dongen, Ferry Eskens, Morgan Finlay, Fatima Menas, Ozlem Yildirim